Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trialKwee Yong, Rakesh Popat, William Wilson et al.|The Lancet Haematology|2022Cited by 25
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A. Chapman, Kwee Yong, Jonathan Sive et al.|Blood|2018Cited by 20
Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trialLucy Brazil, Susan Short, Angela Swampillai et al.|Neuro-Oncology Advances|2020Cited by 18
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Kwee Yong, María Cuadrado et al.|British Journal of Haematology|2021Cited by 15
Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon StudyKwee Yong, Roger G. Owen, Rakesh Popat et al.|Blood|2019Cited by 8